“Breast cancer is a complex disease with many distinct subtypes, each having its own unique biology. While cancer research and drug development have historically focused on understanding the biology of the tumor itself, the field is moving toward a more holistic approach that goes beyond the tumor to examine the role that the tumor microenvironment and host immune response play,” said
The nCounter™ BC 360 Panel and data analysis service categorize disease heterogeneity using 24 biological signatures including the foundational PAM50 signature for breast cancer intrinsic subtyping, breast cancer receptor signaling, measures of DNA damage repair deficiency, inhibitory immune signaling and immune cell population abundance. The Panel provides an easy-to-use workflow that allows researchers to go from sample-to-data in 24 hours with less than 30 minutes of hands-on time. The BC 360 Panel is the second in a series of comprehensive cancer research panels, following the launch of the PanCancer Immuno-Oncology (IO) 360™ Panel in the fall of 2017.
The PanCancer IO360 panel consists of 770 genes and is designed to characterize mechanisms of tumor immune evasion and identify targetable therapeutic pathways by leveraging several gene signatures to describe key biological processes. The panel is designed around the Tumor Inflammation Signature (TIS), an 18 gene signature which measures the presence or absence of a peripherally suppressed adaptive immune response within the tumor that enriches for patient response to a variety of different cancer immunotherapies (Warren & Cesano https://www.ncbi.nlm.nih.gov/pubmed/29393888).
To learn more about the use of NanoString’s 360 series panels in translational research and signature development, please join
Date and Time: Monday, 16 April,
Location: Spotlight Theatre A, Hall A,
Joseph Beechem Ph.D.,
The BC 360 Panel and the IO 360 Panel are for research use only and are not for use in diagnostic procedures.
About NanoString Technologies, Inc.
For more information, please visit www.nanostring.com.
Vice President, Investor Relations & Corporate Communications
Source: NanoString Technologies, Inc.